PREVENTION OF ISCHEMIC EMBOLISM IN HCM PATIENTS WITHOUT PRE-DOCUMENTED ATRIAL FIBRILLATION

Yuko Wada(Shiga University of Medical Science), Hisao Ogawa(Kumamoto University Hospital), Takeshi Aiba(National Cerebral and Cardiovascular Center), Ḱazunori Toyoda(National Cerebral and Cardiovascular Center), Hideaki Kanzaki(National Cerebral and Cardiovascular Center), Toshihisa Anzai(Hokkaido University), Taka‐aki Matsuyama(National Cerebral and Cardiovascular Center), Hatsue Ishibashi‐Ueda(United Cerebral Palsy), Kengo Kusano(Northwestern University), Takashi Noda(Tohoku University), Yoshiaki Morita(Osaka City University), Yasuo Sugano(keiyu Hospital), Koji Miyamoto(National Cerebral and Cardiovascular Center), Satoshi Yasuda(Tohoku University)
Journal of the American College of Cardiology
March 1, 2015
10.1016/s0735-1097(15)60936-6
Cited by 0

Related Papers

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials
|The Lancet|2014|2.7k
Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure.
|Circulation|1994|1.3k
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
|The Lancet|2017|1.3k
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial
|The Lancet|2017|881